Pyxis Oncology, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$11M
Cost of Revenue
$2M
R&D↑+54.8% +$8M
$22M
D&A↑+426.7% +$2M
$3M
Operating Income↑+1.2% +$293K
$-23M
EBITDA↑+426.7% +$2M
$3M
Interest Income↑+158.6% +$138K
$225K
Other Income/Expense↓-48.4% -$1M
$1M
Pretax Income↓-3.8% -$800K
$-22M
Tax Provision
$1M
Net Income↓-3.8% -$800K
$-22M
Operating Margin
-700.4%
Net Margin
-650.9%
Effective Tax Rate
0.0%
Deferred Tax Liabilities
$0
ETR (Continuing Operations)↓-4.4pts
-1.8%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-5.3pts
-0.1%
Operating Lease Cost↑+0.0% +$0
$663K
Income YoY Variation↓-5.1pts
1.2%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↓-0.2pts
-18.8%